FaDu Xenograft Model Service for Head and Neck Cancer

The FaDu cell line, derived from a human hypopharyngeal squamous cell carcinoma, provides a highly reliable and clinically relevant in vivo platform for exploring the biology of pharyngeal malignancies and evaluating the therapeutic efficacy of novel oncology interventions. As a premier pre-clinical contract research organization, Alfa Cytology offers a highly robust, turn-key FaDu Xenograft Model Service designed to provide precise, reproducible, and actionable datasets that accelerate your drug discovery pipeline.

Overview of FaDu Xenograft Model for Head and Neck Cancer

The FaDu xenograft model is an essential and extensively utilized in vivo translational tool in head and neck squamous cell carcinoma (HNSCC) research, specifically for studying tumors originating in the hypopharynx. Established by inoculating human FaDu squamous cell carcinoma cells into immunodeficient mice, this model effectively recapitulates the distinct histological structures, aggressive growth patterns, and complex cellular microenvironmental profiles characteristic of advanced clinical head and neck cancers.

From a biological perspective, the FaDu model is highly regarded for its predictable and rapid growth kinetics, making it exceptionally dependable for high-throughput screening and long-term therapeutic dosing evaluations. The model maintains critical human tumor molecular attributes, including distinct biomarker expressions and standard HNSCC signaling pathways, such as altered EGFR activity and specific p53 tumor suppressor status. Consequently, the model is globally deployed to evaluate the therapeutic potency of small-molecule inhibitors, targeted monoclonal antibodies, novel immunotherapies, and combination radiotherapeutic regimens designed to target resistant head and neck malignancies.

Fig 1. High-throughput in vivo LNP screening identifies LNPHNSCC with preferential tropism for HNSCC solid tumors. (Huayamares SG, et al., 2023)

Cell Line Information: FaDu

The FaDu cell line was established in 1968 from a punch biopsy of a primary hypopharyngeal tumor from a 56-year-old Caucasian male patient diagnosed with squamous cell carcinoma. These cells exhibit an adherent, epithelial morphology under standard in vitro culture parameters and possess well-documented genetic profiles that maintain standard characteristics of human pharyngeal carcinomas.

Our Services

Workflow of FaDu Xenograft Model Construction

• Cell Culture & Quality Control: Human FaDu cells are expanded in vitro using certified nutrient growth media under optimized, strictly monitored environmental parameters. Comprehensive quality control profiling, consisting of mandatory STR authentication and mycoplasma clearance testing, is performed prior to harvesting to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Healthy, standardized immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are carefully selected to match the specific demands of the study layout. The animals are housed within controlled facility parameters for a set duration to establish stable physiological baselines and ensure optimal general health compliance.
• Precision Inoculation: A calibrated suspension of high-viability FaDu cells is prepared and blended with a validated biological matrix carrier to improve spatial distribution and support initial engraftment. The cellular mixture is precisely injected in vivo into the target cohorts via subcutaneous or orthotopic hypopharyngeal routes.
• Longitudinal Growth Tracking: Following successful model establishment and palpable tumor verification, tumor growth kinetics are tracked systematically using high-precision digital calipers under continuous health monitoring. Animal body weights, physiological baselines, and general behavior are routinely cataloged to establish a dependable and comprehensive growth kinetic profile.
• Stratification & Dosing: Once the expanding tumor volumes reach a predetermined, statistically optimal range, the animals are randomized into specific therapeutic cohorts. This stratification step perfectly balances baseline tumor parameters across all groups before customized dosing and efficacy evaluation protocols begin.

Fig 2. FaDu Xenograft Model Construction Workflow

Case Study - FaDu Xenograft Model Development

In a recent pre-clinical validation study, a FaDu xenograft model was constructed to evaluate a novel targeted therapeutic agent designed for head and neck squamous cell carcinomas. Following precision subcutaneous inoculation of human FaDu cells into immunodeficient mice, the tumors achieved a uniform engraftment rate exceeding 90% and exhibited steady, robust growth kinetics over a 28-day monitoring timeline. Tumor-bearing animals randomized into the treatment cohort demonstrated a statistically significant, dose-dependent inhibition of tumor growth compared to the control group, validating the model's high predictive reliability, sensitivity, and robust statistical value for screening targeted pharyngeal cancer therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of advanced squamous cell carcinoma models, providing reliable in vivo platforms for complex head and neck cancer studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your head and neck oncology pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing the FaDu platform, please reach out to us today. The dedicated scientific team at Alfa Cytology is fully prepared to assist you with experimental design, provide operational insights, and deliver the high-quality data your pipeline needs to succeed; please feel free to contact us to get started.

For research use only. Not intended for any clinical use.